IL201934A0 - Controlled release oral formulations of ion channel modulating compounds and uses thereof - Google Patents

Controlled release oral formulations of ion channel modulating compounds and uses thereof

Info

Publication number
IL201934A0
IL201934A0 IL201934A IL20193409A IL201934A0 IL 201934 A0 IL201934 A0 IL 201934A0 IL 201934 A IL201934 A IL 201934A IL 20193409 A IL20193409 A IL 20193409A IL 201934 A0 IL201934 A0 IL 201934A0
Authority
IL
Israel
Prior art keywords
controlled release
ion channel
oral formulations
release oral
modulating compounds
Prior art date
Application number
IL201934A
Other languages
English (en)
Original Assignee
Cardiome Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiome Pharma Corp filed Critical Cardiome Pharma Corp
Publication of IL201934A0 publication Critical patent/IL201934A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
IL201934A 2007-05-04 2009-11-04 Controlled release oral formulations of ion channel modulating compounds and uses thereof IL201934A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91612907P 2007-05-04 2007-05-04
US6615607P 2007-08-01 2007-08-01
US3411908P 2008-03-05 2008-03-05
US3719808P 2008-03-17 2008-03-17
PCT/US2008/062551 WO2008137778A2 (en) 2007-05-04 2008-05-02 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia

Publications (1)

Publication Number Publication Date
IL201934A0 true IL201934A0 (en) 2010-06-16

Family

ID=39691347

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201934A IL201934A0 (en) 2007-05-04 2009-11-04 Controlled release oral formulations of ion channel modulating compounds and uses thereof

Country Status (19)

Country Link
US (3) US20080312309A1 (enExample)
EP (3) EP2468278A1 (enExample)
JP (1) JP2010526102A (enExample)
KR (1) KR20100017648A (enExample)
CN (1) CN101711174A (enExample)
AU (1) AU2008247508B2 (enExample)
BR (1) BRPI0810697A2 (enExample)
CA (1) CA2686396A1 (enExample)
CO (1) CO6241136A2 (enExample)
CR (1) CR11117A (enExample)
EA (1) EA200971025A1 (enExample)
EC (1) ECSP099777A (enExample)
IL (1) IL201934A0 (enExample)
MA (1) MA31664B1 (enExample)
MX (1) MX2009011929A (enExample)
NI (1) NI200900196A (enExample)
NZ (1) NZ581351A (enExample)
TN (1) TN2009000461A1 (enExample)
WO (1) WO2008137778A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
WO2011103398A1 (en) * 2010-02-18 2011-08-25 Aegis Sciences Corporation Detection and quantitation of pain medications in oral fluid specimens

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463395B1 (en) 1990-06-22 1997-05-14 F. Hoffmann-La Roche Ag Detection of poor metabolizers of drugs
US5891696A (en) 1996-08-02 1999-04-06 Panvera Corporation Compositions for cytochrome P450 biotransformation reactions
JP3176342B2 (ja) 1997-08-13 2001-06-18 ファイザー製薬株式会社 薬剤代謝の評価方法及び前記方法用の試薬組成物
BRPI9909282B8 (pt) * 1998-04-01 2021-07-06 Cardiome Pharma Corp compostos de Éter aminociclohexÍlicos e usos dos mesmos.
US7507545B2 (en) * 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US7524879B2 (en) * 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
EP1281755A3 (en) * 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
CA2524034A1 (en) * 2003-05-02 2004-11-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
EP1560812B1 (en) * 2003-05-02 2006-05-10 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US20080063707A1 (en) * 2003-05-02 2008-03-13 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US7345087B2 (en) * 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
EP1868598B1 (en) * 2004-11-08 2014-04-23 Cardiome Pharma Corp. A new dosing regimen for ion channel modulating compounds for treating acute atrial fibrillation in a human
JP5159616B2 (ja) * 2005-06-15 2013-03-06 カーディオム ファーマ コーポレイション アミノシクロヘキシルエーテル化合物の調製のための合成プロセス
WO2009018547A1 (en) * 2007-08-01 2009-02-05 Cardiome Pharma Corp. Extended release formulations containing an ion-channel-modulating compound for the prevention of arrhythmias

Also Published As

Publication number Publication date
CN101711174A (zh) 2010-05-19
MX2009011929A (es) 2010-03-08
WO2008137778A3 (en) 2009-03-12
US20080312309A1 (en) 2008-12-18
TN2009000461A1 (en) 2011-03-31
NI200900196A (es) 2010-03-11
KR20100017648A (ko) 2010-02-16
JP2010526102A (ja) 2010-07-29
CR11117A (es) 2010-02-19
BRPI0810697A2 (pt) 2019-08-27
EP2462933A1 (en) 2012-06-13
ECSP099777A (es) 2010-02-26
AU2008247508A1 (en) 2008-11-13
EP2155334A2 (en) 2010-02-24
CA2686396A1 (en) 2008-11-13
US20150099788A1 (en) 2015-04-09
EP2468278A1 (en) 2012-06-27
AU2008247508B2 (en) 2014-07-10
NZ581351A (en) 2012-07-27
MA31664B1 (fr) 2010-09-01
US20160089361A1 (en) 2016-03-31
CO6241136A2 (es) 2011-01-20
WO2008137778A2 (en) 2008-11-13
EA200971025A1 (ru) 2010-04-30

Similar Documents

Publication Publication Date Title
IL206756A0 (en) Controlled release formulations of levodopa and uses thereof
IL214617A0 (en) Use of controlled release formulations of octreotide
EP2043647A4 (en) FORMULATION WITH TAXED RELEASE AND CORRESPONDING METHODS
PT2119477T (pt) Composição para tratamento de xerostomia ou boca seca
EP2178893A4 (en) ORAL FORMULATIONS FOR PICOPLATIN
GB0710844D0 (en) Potassium ion channel modulators & uses thereof
IL209307A0 (en) Oral formulations of cytidine analogs and methods of use thereof
EP2180873A4 (en) THERAPEUTIC DENTAL COMPOSITION AND RELATED METHODS
IL202785A0 (en) Use of homo-and copolymers for stabilizing active ingredient formulations
PL2173345T3 (pl) Doustna formulacja metadoksyny
EP2173822A4 (en) INK FORMULATIONS AND METHOD FOR PRODUCING INK FORMS
GB0723794D0 (en) Potassium ion channel modulators and uses thereof
GB0619176D0 (en) Ion channel modulators & uses thereof
GB0715103D0 (en) Calcium ion channel modulators and uses thereof
IL196432A0 (en) Nanoparticulate formulations of modafinil
EP1895991A4 (en) MODIFIED RELEASE FORMULATIONS OF ANTI-IRRITABLE DRUGS
IL201934A0 (en) Controlled release oral formulations of ion channel modulating compounds and uses thereof
EP2285219A4 (en) CONTROLLED RELEASE FORMULATIONS OF ALPRAZOLAM
GB0817576D0 (en) Calcium ion channel modulators & uses thereof
EP2291178A4 (en) PRAMIPEXOL FORMULATIONS WITH CONTROLLED RELEASE
ZA201100068B (en) Calcium ion channel modulators & uses thereof
HK1141472A (en) Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia
GB0715107D0 (en) Calcium ion channel modulators and uses thereof
GB0715109D0 (en) Calcium ion channel modulators and uses thereof
GB0715110D0 (en) Calcium ion channel modulators and uses thereof